Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Diamond-Blackfan Anemia

Blood & Immune

Diamond-Blackfan Anemia (DBA) Clinical Trials and Treatments

Also called DBA, pure red cell aplasia, congenital hypoplastic anemia

Diamond-Blackfan anemia (DBA) is a rare genetic bone marrow failure syndrome, caused by a new gene change in somewhat more than half of cases and inherited from a parent in the rest, characterized by selective hypoplasia of erythroid progenitor cells, resulting in moderate to severe anemia with macrocytosis. The condition is caused by mutations in genes encoding ribosomal proteins (particularly RPS19 in 25% of cases) and other ribosomal biogenesis factors (RPL5, RPL11, RPS7, others), disrupting ribosome assembly, protein synthesis, and innate immune responses.

In plain words, Diamond-Blackfan anemia is a rare genetic condition where the bone marrow does not make enough red blood cells. Without enough red blood cells, people can feel tired, look pale and get short of breath.

Get an email when new Diamond-Blackfan Anemia trials open or the FDA decides. Get alerts

Diamond-Blackfan Anemia

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 4 studies with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines1

Corticosteroids

Diamond-Blackfan Anemia has 1 FDA-approved medicine, 7 open or active clinical trials (7 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Diamond-Blackfan Anemia

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Diamond-Blackfan Anemia

Pathophysiology involves impaired erythroid differentiation with relative sparing of myeloid and megakaryocytic lineages. Approximately 50% of DBA patients have associated physical abnormalities including thumb or radial ray defects, short stature, cardiac defects (especially septal defects), urogenital anomalies, cleft palate, and renal anomalies.

Keep reading about Diamond-Blackfan Anemia

Most patients present before age 2 years with failure to thrive, pallor, and macrocytic anemia. The disorder is characterized by absent or severely reduced erythroid progenitors on bone marrow examination with normal myeloid and megakaryocytic lineages. Fetal hemoglobin (HbF) typically elevated. Diamond-Blackfan patients have significantly increased risk of acute leukemia and solid tumors including osteosarcoma, which requires surveillance. Many patients achieve spontaneous remission in childhood, though relapse possible.

What are the symptoms of Diamond-Blackfan Anemia?

These are common symptoms of Diamond-Blackfan Anemia, and how strong they are varies from person to person.

  • Severe anemia presenting by age 1 year
  • Fatigue, dyspnea, and pallor
  • Physical abnormalities in 50% (thumb defects, short stature)
  • Macrocytic anemia
  • Absent or severely reduced reticulocyte response
  • Normal white blood cells and platelets initially

Who gets Diamond-Blackfan Anemia?

Presents in infancy or early childhood, typically before age 2 years with peak presentation by age 3-6 months. Affects males and females equally. Most cases are autosomal dominant, caused by a change in a ribosomal protein gene. About 45% are inherited from a parent, who has a 50% chance of passing it to each child, and the rest arise as new changes. Rare cases caused by the GATA1 or TSR2 genes affect only boys and pass through mothers who carry the change.

Heterozygous carriers may have mild phenotype. No significant ethnic or racial predisposition identified. Geographic variation in prevalence underexamined. Family history important in approximately half of cases.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Diamond-Blackfan Anemia?

There is currently 1 FDA-approved medication for Diamond-Blackfan Anemia.

Corticosteroids
triamcinolone, methylprednisolone, prednisolone, hydrocortisone, prednisone, dexamethasone, betamethasone

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Diamond-Blackfan Anemia

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Diamond-Blackfan Anemia resources

Reputable organizations and medical references for learning more about Diamond-Blackfan Anemia, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Diamond-Blackfan Anemia

Use this Diamond-Blackfan Anemia clinical trial finder to see the 7 studies recruiting patients in the United States and worldwide, with eligibility criteria in plain English. Of these, 3 test a treatment and 4 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

7 active trials worldwide
Filter:
Sort:
RecruitingObservational study, no treatment givenRecently updatedNCT00027274

Cancer in Inherited Bone Marrow Failure Syndromes

Sponsor: National Cancer Institute (NCI)

Background:

A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders.

Pathogenic variant(s) in IBMFS genes are relevant to carcinogenesis in sporadic cancers.

Ages 1 Day to 100 Years2 locations
Started Nov 2001Updated 6 days agoCompletion date not listed
RecruitingObservational study, no treatment givenRecently updatedNCT07186179

Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)

Intervention: Mobilization Regimen

Sponsor: Northwell Health

Gene therapy is a new possible treatment for the anemia of DBAS. Gene therapy will soon be available for patients with RPS19-mutated DBAS. This involves inserting the corrected RPS19 gene into the cells, leading to correction of the anemia.

Ages 3 Years to 30 Years1 location
Started May 2026Updated 2 weeks agoEst. Oct 2028 (~1y 10m)
RecruitingTreatment trialPhase 2Recently updatedNCT04099966

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

Intervention: alpha beta depletion

Sponsor: Mitchell Cairo

Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.

Ages 1 Day to 30 Years1 location
Started Apr 2021Updated 3 weeks agoEst. Dec 2026 (~1 month)
RecruitingTreatment trialPhase 1/2Updated a few months agoNCT03653338

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

Intervention: CD3/CD19 depleted leukocytes, CD45RA depleted leukocytes, Hydroxyurea, Rituximab, Alemtuzumab, Fludarabine, Thiotepa

Sponsor: Paul Szabolcs

The purpose of this study is to evaluate what effect, if any, mismatched unrelated volunteer donor and/or haploidentical related donor stem cell transplant may have on severe sickle cell disease and other transfusion dependent anemias. By using mismatched unrelated volunteer dono...

Ages 5 Years to 40 Years1 location
Started Aug 2018Updated 3 months agoEst. Aug 2028 (~1y 8m)
RecruitingTreatment trialPhase 1Updated a few months agoNCT07476183

Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia

Intervention: APR-2020

Sponsor: Apriligen, Inc.

Brief summary

The goal of this clinical trial is to learn if APR-2020 is safe and can help treat Diamond-Blackfan Anemia (DBA) in adolescents and children. The main questions it aims to answer are:

* Is APR-2020 safe and well tolerated?

Ages 2 Years to 25 Years2 locations
Started Apr 2026Updated 4 months agoEst. Apr 2027 (~5 months)
Find Diamond-Blackfan Anemia trials near you, ranked by distance →
Active trial locations8 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 1
Phase 2
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Diamond-Blackfan Anemia trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Diamond-Blackfan Anemia foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Diamond-Blackfan Anemia patient communities

Facebook groups, Reddit communities and YouTube channels where Diamond-Blackfan Anemia patients, caregivers and advocacy groups talk.

Questions people ask about Diamond-Blackfan Anemia